🔗 Share this article

As the United States proceeds with historic changes to its vaccination schedules, a particular individual has emerged somewhat surprisingly: Høeg, a US-based sports medicine doctor and epidemiologist who initially gained attention by questioning coronavirus vaccinations in the global health crisis and has zeroed in on alleged deaths following COVID-19 vaccination in her brief position at the Food and Drug Administration.

Planned Overhauls to Pediatric Vaccine Schedule

Agency leaders planned to unveil major changes to the pediatric vaccine schedule recently, aligning the US with the Danish immunization schedule, it is understood – a significant shift that would place the US out of alignment with a large portion of the global community with insufficient data for improved outcomes. This reveal has been delayed until the new year.

Rather than the director of the vaccine center, Dr. Høeg is set to speak at the gathering. She was just designated interim head of the FDA’s drug evaluation center, the fifth person to run the center this calendar year.

A New Direction at the Agency

The acting appointment may indicate a tighter collaboration between the pharmaceutical and vaccine branches as Dr. Høeg and Dr. Prasad consolidate power at the FDA – and it suggests a greater focus upon reevaluating previously authorized vaccines at the FDA.

Dr. Høeg has repeatedly called for ending specific pediatric immunization guidelines in the US in order to be more in line with the Danish model, a society with comprehensive healthcare and a number of inhabitants approximately the size of Wisconsin’s.

So far statements, she has kept her attention on immunizations – traditionally the responsibility of Prasad, head of the FDA’s vaccine center – instead of medication approval.

Questions Over Background

Dr. Høeg has little discernible experience in pharmaceutical research, approval processes or administrative roles, which has been typical for past heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the commissioner and the vaccine center since earlier this year.

“She doesn’t seem to have the necessary background” for overseeing the pharmaceutical oversight division, said Dr. Jonathan Howard. “She lacks experience running a clinical trial. She has no expertise in managing a major agency. She is not an expert in pharmaceutical oversight.”

Past commissioners of the center would “be deeply familiar with regulatory frameworks and the science of pharmaceutical innovation”, said a former acting FDA commissioner. “Objectively, she has not acquired the type of experience that previous people who ran CBER have had.”

CDER has an vast workload at the FDA, the former commissioner stated.

“The public just pays attention on the innovative therapies, but the generic drug division authorizes numerous generic drugs. There is also a biosimilars program, over-the-counter program and more, and each of these have to be supervised,” Dr. Woodcock noted. “The responsibility you don’t keep your eye on, that’s the thing that I always told people is going to come back to haunt you.”

Furthermore, a significant management component to the role, which oversees in excess of 5,000 personnel. “It’s a huge management job, if you perform it correctly,” the former official added.

Official Statement and Disputed Programs

Regarding inquiries about Dr. Høeg's credentials and whether this appointment represents increased cooperation among regulatory chiefs on vaccines, a spokesperson stated that the “inquiries rely on flawed presumptions”.

“This background aligns with the responsibilities of her job,” the official explained, pointing to the period Dr. Høeg spent guiding the agency head on “drug safety and oversight research, including predictive safety algorithms and shot safety tracking”.

As the temporary head, Høeg takes over the agency head's new expedited review system, a disputed one-day therapy clearance system that apparently concerned her former heads. “By what process are these drugs being picked for this fast-track system? Who is making the decisions?” Howard said. “There is a lot of lack of transparency occurring at the regulatory body right now.”

Overall, he remarked, “the FDA appears to be shifting towards less stringent regulations of most medications, except for vaccines.”

Established History on Vaccines

Concerning immunizations, Dr. Høeg has a clearer, if problematic, history, Howard observe. She released a research paper using unverified crowd-sourced reports to determine the rate of myocarditis after COVID-19 vaccination. She consulted for the state of Florida surgeon general Dr. Joseph Ladapo, who reportedly have changed statistics to imply COVID-19 vaccinations are pose a greater threat than they are.

Included in her “policy goals” for the new federal leadership encompassed altering guidelines for recently developed shots and ending “optional” vaccines, she remarked after the election on a audio program. At the FDA, Dr. Høeg has reportedly proposed excluding young men from receiving COVID-19 vaccines.

“She is an thorough ideologue who begins with her beliefs and reverse-engineers to retrofit the evidence in a extremely misleading, fraudulent manner,” Dr. Howard said.

Gaining Influence and a “Push for Payback”

Dr. Høeg aligned with other dissenters, {like|